Original articleA snapshot of cancer-associated thromboembolic disease in 2018–2019: First data from the TESEO prospective registry
Introduction
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with cancer [1]. Both pathologies interrelate at a deep biological level with numerous interactions between key elements of the hemostatic system and cancer cell programs [2]. Cancer-associated thrombosis (CAT) falls within a panorama of growing complexity in oncology, with the appearance of new anticoagulant therapies, emerging molecular data [3], and new antineoplastic treatments associated with thrombotic risk. Most targeted therapies that have proven benefit in recent clinical trials, such as CDK4/6 inhibitors, immune checkpoint inhibitors, or antiangiogenics, are linked to increased risk of VTE [4], [5], [6]. Managing CAT is challenging, given the higher risk of rethrombosis and severe bleeding with anticoagulant treatment [7]. Moreover, people with cancer exhibit numerous specific characteristics, such as the use of chemotherapy, hormone therapy, or targeted therapies with specific mechanisms of action and toxicities, increased incidental thrombosis, and chronic comorbidities (hepatic, renal, thrombocytopenia, etc.) that add an extra layer of complication to decision-making.
Despite the multiple clinical practice guidelines regarding the prevention and management of CAT, numerous critical decisions about anticoagulant therapy, primary thromboprophylaxis, or management of special cases continue to be made with low levels of evidence [8]. The problem is exacerbated, in light of the high percentage of these patients who will not be eligible or will be under-represented in clinical trials, given the complexity of their clinical situation [9].
The Spanish Society of Medical Oncology's (SEOM) registry of thrombosis and embolism [TESEO] was born in 2018 to detect emerging epidemiological trends in CAT and to analyze outcomes in real-world clinical practice of cases that run the gamut from ordinary to the most highly complex and exceptional (e.g., those with high risk of bleeding, incidental episodes, etc.). With these premises, we present the first data coming out of the TESEO registry (NCT03855592) that provide a prospective snapshot of CAT (2018-2019).
Section snippets
Patients and study design
TESEO is a prospective registry under the auspices and management of SEOM with the collaboration of 34 Spanish hospitals that recruit consecutive cases of CAT [10].
Eligibility criteria consist of individuals ≥18 years of age with cancer, with a VTE event confirmed by objective imaging technique (Doppler ultrasound, CT angiography scans, high probability scintigraphy, CT scheduled to assess tumor response or for other reasons, etc.). In the case of multiple episodes, only the first event is
Variables and objectives
The aim of this study is to provide an epidemiological description of CAT in Spain. The study variables included clinical and molecular characteristics of the neoplasms, VTE-associated variables, prognostic evaluation of the episodes, and anticoagulant therapy. The study endpoints comprise overall survival, 15-day complication rate, venous rethrombosis, and bleeding. Overall survival (OS) was defined as the time since development of VTE and all-cause mortality, bearing in mind the
Patients and oncological context
At the time of analysis, 939 patients diagnosed with VTE between July 2018 and December 2019 had been recruited. The baseline characteristics of these individuals are summarized in Table 1. The most common tumors were high incidence ones: colorectal (n=201, 21.4%), non-small cell lung (n=181, 19.2%), and breast (n=105, 11.1%), followed by of other neoplasms associated with high thrombotic risk (pancreas, stomach, ovary, etc.) (see detailed list in A.1).
Most had an active tumor or stage IV
Discussion
This analysis describes the situation of CAT during the 2018-2019 period, based on the initial data from the SEOM's registry of thrombosis, TESEO. The reason for undertaking this project has been the perception that cancer treatment is developing at breakneck speed, with transformations that force us to reassess aspects having to do with support [16], re-think the thrombotic risk of new survivors [17], as well as the effect new antitumor drugs have on hemostasis [4], [5], [6]. Added to that is
Funding
The study has been funded by a restricted grant from Sanofi, S.A. This entity has not contributed to the study design, data analysis, interpretation of the results, drafting of the document, or in the decision regarding publication in any way.
Research involving human participants
All procedures followed are in accordance with the ethical standards of the committee in charge of human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
Informed consent or a substitute for it was obtained from all patients before they were included in the study.
CRediT authorship contribution statement
Alberto Carmona-Bayonas: Formal analysis, Writing - original draft, Writing - review & editing. David Gómez: Formal analysis, Writing - original draft, Writing - review & editing. Eva Martínez de Castro: Formal analysis, Writing - original draft, Writing - review & editing. Pedro Pérez Segura: Formal analysis, Writing - original draft, Writing - review & editing. José Muñoz Langa: Formal analysis, Writing - original draft, Writing - review & editing. Paula Jimenez-Fonseca: Formal analysis,
Declaration of Competing Interest
ACB: consulting/advisory role: Roche, Rovi, Sanofi, LeoPharma, Pfizer, Esteve; travel grants: Ipsen, Roche, Novartis. DG: None. EMC: Consultant or Advisory Role: Pfizer, Amgen. Speaking: Roche, Pfizer, Amgen, Sanofi, LeoPharma, Rovi, Celgene. Travel, Accommodations: Roche, Pfizer, Celgene, Sanofi. PPS: Consultant or Advisory Role: Novartis, BMS, Merck. Travel, Accommodations: MSD, Merck. JML: Consultant or Advisory Role: LEO Pharma. Speaking: Sanofi, LeoPharma. Travel, Accommodations:
Acknowledgments
SEOM for sponsoring this study. Priscilla Chase Duran for editing and translating the manuscript. The mFAR team for the support of the website registry.
References (39)
- et al.
Venous thromboembolism in cancer patients receiving immunotherapy
Blood
(2018) - et al.
Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors
J Thromb Haemost
(2020) Lensing AW a, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
Blood
(2002)- et al.
On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism
Thromb Res
(2016) - et al.
Anticoagulation S on C of. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH
J Thromb Haemost
(2015) - et al.
Intensive care in cancer patients in the age of immunotherapy and molecular therapies: Commitment of the SEOM-SEMICYUC
Med Intensiva
(2018) - et al.
The clinical course of venous thromboembolism may differ according to cancer site
Am J Med
(2017) - et al.
High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients
J Thromb Haemost
(2010) - et al.
Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modeling: the EPIPHANY index
Br J Cancer
(2017) - et al.
Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment
Cancers (Basel)
(2018)
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
Eur Respir J
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis
JAMA
FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence
Clin Transl Oncol
Real-life use of anticoagulants in venous thromboembolism with a focus on patients with exclusion criteria for direct oral anticoagulants
Clin Pharmacol Ther
TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM)
Clin Transl Oncol
R: a language and environment for statistical computing
ggplot2: Elegant Graphics for Data Analysis
Easily Tidy Data with ‘spread ( )’and ‘gather ( )’ Functions
CRAN Repos
Long-term risk of venous thromboembolism in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study
J Clin Oncol
Cited by (25)
Acute venous thromboembolism in patients with brain cancer: clinical course
2023, Research and Practice in Thrombosis and HaemostasisDecoding risk: Caravaggio's insights into risk factors for anticoagulation in cancer-associated thrombosis
2023, European Journal of Internal MedicineRisk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism
2023, European Journal of Internal MedicinePerformance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism: Insights From the Hokusai-VTE Cancer Study
2022, JACC: CardioOncologyCitation Excerpt :Although it is known that a worsening of ECOG status reflects a worsening of the underlying cancer and increases the risk for death, the finding that cancer-associated risk for thrombosis and bleeding may increase concomitantly is novel and, in our view, clinically relevant. Our results are supported by recent data that show a disproportionally high incidence of thrombosis recurrence in patients with stage IV cancer, even in the era of immunotherapy.17,18 Conversely, patients with earlier stage cancer are less likely to develop VTE recurrence after an episode of cancer-associated VTE.19
Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment—A report from ICTHIC 2021
2022, Research and Practice in Thrombosis and Haemostasis